CLINICAL TRIALS PROFILE FOR IOTHALAMATE SODIUM
✉ Email this page to a colleague
All Clinical Trials for IOTHALAMATE SODIUM
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00270829 ↗ | Renal Effects of Intrarenal Nesiritide | Terminated | University of Maryland | Phase 4 | 2005-12-01 | The impact of nesiritide in CHF is unclear, but it is possible that systemic vasodilation leads to adverse consequences even if the direct renal effects are positive. Therefore, this study will look at the effects of direct intrarenal administration of nesiritide on GFR and RPF. |
| NCT00270829 ↗ | Renal Effects of Intrarenal Nesiritide | Terminated | University of Maryland, Baltimore | Phase 4 | 2005-12-01 | The impact of nesiritide in CHF is unclear, but it is possible that systemic vasodilation leads to adverse consequences even if the direct renal effects are positive. Therefore, this study will look at the effects of direct intrarenal administration of nesiritide on GFR and RPF. |
| NCT01836809 ↗ | Nesiritide and Renal Function After the Total Artificial Heart | Terminated | Virginia Commonwealth University | Phase 4 | 2013-04-01 | The prevalence of renal dysfunction after implantation of the artificial heart is high. The infusion of exogenous B-type natriuretic peptide (BNP) after implantation of the total artificial heart (TAH) improves renal function in a sustained manner. The renal protective and hormone-modulating effects of nesiritide may be enhanced with ventriculectomy compared to heart failure surgery that leaves the native myocardium intact. The goal of this project is to determine the renal protective effects of nesiritide after implantation of a mechanical device. |
| NCT01970176 ↗ | Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2) | Completed | Mayo Clinic | Phase 1/Phase 2 | 2014-01-09 | To determine the effect of 12 weeks of chronic PDEV inhibition with Tadalafil versus placebo on basal cardiorenal and humoral function and on the integrated cardiorenal and humoral response to acute sodium loading in subjects with preclinical systolic dysfunction (PSD) and renal (kidney) dysfunction. |
| NCT02058095 ↗ | Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Diastolic Cardiomyopathy (Aim3) | Completed | Mayo Clinic | Phase 1/Phase 2 | 2014-03-01 | To determine the effect of 12 weeks of chronic PDEV inhibition with Tadalafil versus placebo on basal cardiorenal and humoral function and on the integrated cardiorenal and humoral response to acute sodium loading in subjects with preclinical Diastolic dysfunction (PDD) and renal (kidney) dysfunction |
| NCT03019653 ↗ | Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome | Enrolling by invitation | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 | 2017-01-01 | The purpose of this study is to look at kidney function and hormonal function in patients with a history of heart failure and kidney dysfunction, and to see how the use of a new drug, ANX-042, affects those functions. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for IOTHALAMATE SODIUM
Condition Name
Clinical Trial Locations for IOTHALAMATE SODIUM
Trials by Country
Clinical Trial Progress for IOTHALAMATE SODIUM
Clinical Trial Phase
Clinical Trial Sponsors for IOTHALAMATE SODIUM
Sponsor Name
